Certain glucagon-like peptide-1 receptor agonists (GLP1-RAs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors should be used for cardiorenal protection in people with high cardiovascular (CV) risk, heart failure (HF), or chronic kidney disease (CKD)
CJC-1295 has several modifications for improved pharmacokinetics, including the substitution of four amino acids in the original 29 amino acid chain, which improves the peptides stability and effectiveness [4, 5, 6]: At the second position, L-alanine is replaced with D-alanine, heightening resistance to the enzyme dipeptidyl peptidase-4 (DPP-4), which plays a crucial role in deactivating many peptide-based medications
Also, I love that it includes Glycine and B12
However, heart failure hospitalizations were significantly reduced by 30% in the patients treated with ertugliflozin (HR 0.70
Private prescriptions would follow MHRA licensing and professional guidelines